Tina Catalano

Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

Stephen M. Ansell, Michael B. Maris, Alexander M. Lesokhin et al. · Clinical Cancer Research · 2021 · 183 citations · Full text

CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study

Krish Patel, Jeffrey A. Zonder, Dahlia Sano et al. · Blood · 2021 · 26 citations

Confirmation of Biosimilarity in a Pharmacokinetic/Pharmacodynamic Study in Healthy Volunteers for an Analytically Highly Similar Pegfilgrastim

Kalpna Desai, Tina Catalano, Gurinder Rai et al. · Clinical Pharmacology in Drug Development · 2016 · 23 citations · Full text

A Single Direct Intratumoral Injection of TTI-621 (SIRPαFc) Induces Antitumor Activity in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Preliminary Findings Employing an Immune Checkpoint Inhibitor Blocking the CD47 Do Not Eat Signal

Christiane Querfeld, John A. Thompson, Matthew H. Taylor et al. · Blood · 2017 · 17 citations

Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study

Krish Patel, Radhakrishnan Ramchandren, Michael B. Maris et al. · Blood · 2020 · 15 citations